Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

George Sakoulas, MD34 enrolled

Overview

The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019 (COVID-19). The principal investigator has successfully utilized IVIG for patients infected with the influenza virus. The investigator wants to find out if IVIG is equally effective in COVID-19 infection patients, and if IVIG will give the immune system some help to clear the infection naturally.

This is an investigator initiated, open label, multicenter, two arm, randomized study to compare the impact of adding IVIG to the Standard of Care (SOC) to the SOC without IVIG. Randomization will be 1:1. The goal of this study is to identify whether or not IVIG can halt the progression to respiratory failure requiring mechanical ventilation in subjects admitted to the hospital with confirmed COVID-19. The addition of IVIG to the standard of care treatment for these patients may be beneficial in abating acute lung injury in subjects with SARSCoV-2 induced hypoxia that results in organ injury.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Sars-CoV2

Interventions

OctagamDRUG

Standard of Care plus Octagam infusion for 3 days.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed COVID-19 positive test result (including presumptive positive). * Hospitalization * Requiring ≥4 liters/min O2 nasal cannula to maintain oxygen saturation ≥ 92%, but not mechanically ventilated * Age ≥18 years old. * Access to a phone in the hospital room or an electronic device that is capable of receiving phone calls and/or video calls and/or e-mail. * Able to read/write/speak English or Spanish fluently. * Subjects must have the capacity to provide consent or an appropriate Legally Authorized Representative (LAR) to provide informed consent. provide informed consent, and provide authorization of use and disclosure of personal health information. * Negative pregnancy test for women of childbearing potential. Exclusion Criteria: * Severe allergy to any IVIG product formulation * History of DVT, PE, thromboembolic stroke or other thrombotic events * Hypersensitivity to corn. Octagam® contains maltose which is a sugar derived from corn. * Uncontrolled hypertension (SBP\>180 mm Hg or DBP\>120mmHg) * Active participant in another research treatment study * Mechanically ventilated patient * Code status is Do Not Resuscitate or Do Not Intubate

Locations (2)

Sharp Grossmont Hospital

La Mesa, California, United States

Sharp Memorial Hospital

San Diego, California, United States

Outcomes

Primary Outcomes

Mechanical Ventilation

Number of subjects requiring mechanical ventilation due to respiratory failure

Time frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days

Secondary Outcomes

Oxygen Therapy

Number of days requiring oxygen therapy

Time frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days

Length of Stay

Number of days in hospital

Time frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 60 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.